GlassScriptPhysician profile
Ellen Boynton
NPI 1699073916
$2,917.30
in general payments reported to CMS, 2019-2025
24 companies · $993 in 2025
The $993 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $475 · 2022: $515 · 2023: $655 · 2024: $280 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,927.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $856.22 | 2021-2025 | Farxiga, Fasenra, Tezspire |
| Genzyme Corporation | $312.36 | 2025 | |
| Glaxosmithkline, LLC. | $198.61 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $174.46 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $167.93 | 2021-2024 | Mounjaro, Trulicity, Zepbound |
| Genentech USA, INC. | $136.26 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $124.98 | 2025 | Neffy |
| Amarin Pharma, INC. | $113.14 | 2021-2022 | |
| Organon LLC | $106.62 | 2025 | Vtama |
| Abbvie INC. | $98.05 | 2021-2023 | |
| Csl Behring | $94.15 | 2025 | Andembry, Hizentra, Haegarda |
| Boston Scientific Corporation | $89.66 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $82.10 | 2023 | Freestyle Libre 3 |
| Amgen INC. | $79.66 | 2023-2024 | Repatha, Otezla |
| Exact Sciences Corporation | $60.46 | 2023-2024 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $50.30 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $30.44 | 2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $28.97 | 2025 | Cuvitru |
| Lucid Diagnostics INC. | $22.61 | 2022 | |
| Seqirus USA INC | $19.73 | 2024 | Fluad, Flucelvax |
| Pfizer INC. | $19.72 | 2023 | |
| Grifols USA, LLC | $18.32 | 2025 | Xembify |
| Kaleo, INC. | $17.27 | 2021 | |
| Hologic Sales and Service, LLC | $15.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Boynton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.